ALLAKOS INC. - COMMON STOCK

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

27 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

10 Oct 2024 16:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

07 Aug 2024 16:02:00 By Nasdaq GlobeNewswire

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

25 Jun 2024 16:02:00 By Nasdaq GlobeNewswire

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

28 May 2024 07:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

09 May 2024 16:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 Mar 2024 16:02:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

26 Feb 2024 07:02:00 By Nasdaq GlobeNewswire

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

12 Feb 2024 07:02:00 By Nasdaq GlobeNewswire

Allakos Announces a Restructuring to Focus on Development of AK006

16 Jan 2024 07:02:00 By Nasdaq GlobeNewswire

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

16 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

13 Nov 2023 16:02:00 By Nasdaq GlobeNewswire

Allakos Appoints Neil Graham to its Board of Directors

30 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

09 Aug 2023 16:02:00 By Nasdaq GlobeNewswire

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

02 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

12 Jun 2023 07:02:00 By Nasdaq GlobeNewswire

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

05 Jun 2023 07:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

09 May 2023 16:02:00 By Nasdaq GlobeNewswire

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

06 Mar 2023 16:02:00 By Nasdaq GlobeNewswire

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

29 Nov 2022 07:02:00 By Nasdaq GlobeNewswire